Ultrasound assessment of salivary glands in patients with primary Sjögren's syndrome treated with rituximab: Quantitative and Doppler waveform analysis
Authors Sandrine Jousse-Joulin, Valérie Devauchelle-Pensec, Johanne Morvan, Bruno Guias, Yvon Pennec, et al
Published 15 January 2008 Volume 2007:1(3) Pages 311—319
Sandrine Jousse-Joulin1,2, Valérie Devauchelle-Pensec1,4, Johanne Morvan1, Bruno Guias2, Yvon Pennec3, Jacques-Olivier Pers4, Capucine Daridon4, Christophe Jamin4, Yves Renaudineau, Isabelle Quintin Roué6, Béatrice Cochener5, Luc Bressollette2, Pierre Youinou4, Alain Saraux1,4
1Rheumatology Unit, 2Doppler Ultrasound Unit, 3Internal Medicine Unit, la Cavale Blanche Hospital, Brest Teaching Hospitals, Brest, France; 4Immunology Unit, 5Ophthalmology Unit, 6Pathology Unit, Morvan Hospital, Brest Teaching Hospitals, Brest, France
Objectives: Noninvasive objective tests are needed to diagnose primary Sjogren’s syndrome (pSS) and to evaluate treatment responses. Ultrasound imaging of the salivary glands is rapid and noninvasive. Recent open-label studies suggested that anti-CD20 (rituximab) may be effective in pSS. The purpose of this study was to look for ultrasound evidence of the effects of rituximab in pSS.
Methods: We compared 16 patients fulfilling the new American-European consensus group criteria for pSS to 9 controls, using B-mode ultrasound features (parenchymal homogeneity and gland size) and Doppler waveform analysis of the transverse facial artery of parotid glands. We compared the same parameters in the patients before and after 12 weeks of intravenous rituximab therapy.
Results: Compared to controls, untreated patients had significant abnormalities in salivary gland structure (p < 0.0001) and parotid size (2.05 ± 0.33 cm versus 1.70 ± 0.28 cm; p = 0.001). Doppler waveform analysis showed significant differences before, but not after, lemon stimulation between untreated patients and controls. After rituximab treatment, significant size reductions were noted in the parotids (2.05 ± 0.3 cm at baseline and 1.86 ± 0.27 cm at week 12; p = 0.002) and submandibular glands (2.02 ± 0.54 cm at baseline and 1.66 ± 0.34 cm at week 12; p = 0.001). Doppler resistive indices after lemon stimulation were significantly increased after rituximab treatment.
Conclusion: Salivary gland measurements and blood inflow responses to salivary stimulation as assessed by ultrasound hold promise as objective noninvasive tools for evaluating rituximab effects in patients with pSS.
Keywords: ultrasonography, primary Sjögren’s syndrome, rituximab